Clinical Research Needs To Move ‘Out Of The Ivory Tower,’ FDA’s Woodcock Urges
Executive Summary
Acting Commissioner says she is ‘really going to be pushing’ to have clinical trials conducted in the community. CDER’s Cavazzoni and CBER’s Marks discuss master protocols, decentralized trials, and real world evidence at DIA’s annual meeting.
You may also be interested in...
‘Elites’ Need To Understand Clinical Development Remains Necessary For Drug Discovery, Woodcock Says
US FDA’s principal deputy commissioner continues to preach clinical trial reform, saying stakeholders must remember that understanding a molecule does not equate to understanding its impact on the body.
Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?
Companies like Bayer and AstraZeneca are seeing what a difference decentralization makes as CVS is rapidly expanding its clinical research business.
Robert Califf Offers ‘A Few Words In Favor Of The Tortoise’ When Conducting Clinical Trials
The once and likely future FDA commissioner emphasizes value of randomized controlled trials, the fact that not all trials are good for people, and how decentralization and digitization are leaving people behind. Takeda exec questions if industry is being bold enough.